Stable Virus Packaging Cell Lines (SJ-95-0005)

Technology Name
(St. Jude Reference #)
Stable Virus Packaging Cell Lines (SJ-95-0005)
Description One of the major limitations of human gene therapy vectors has been the low rate of infectivity due to the relatively low expression of membrane proteins that serve as the viral receptor. This invention describes the construction of a stable virus packaging cell line which utilizes the VSV-G (vesicular stomatitis virus) membrane protein as the viral receptor, which has a much broader host range than  vectors currently in use in gene therapy trials. Vector particles can also be concentrated to high titers.  This packaging cell line could be developed by a pharmaceutical company or clinical grade reagent supplier to produce high titer viral particles with a broad host range whichexpress a particular gene of interest for use as agene therapy treatment.
Keywords Gene therapy, packaging cell line, VSV (vesicular stomatitis virus)
Granted Patents or Published Applications U.S. Patent No. 5,750,396
Related Scientific References Yang,  et al., “Vesicular stomatitis virus (VSV) pseudotyped murine retrovirus mediates gene transfer into human hematopoietic cells” Blood 84(10); Suppl. I:358a (December 1991) Abstract No. 1417; Yang, et al., “Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein” Hum Gene Ther 6(9):1203-13 (Sept 1995).
Licensing Opportunities We are currently seeking licensing opportunities in all fields for the development of this technology.  This technology is co-owned with Genetic Therapy, Inc. a subsidiary of Novartis.


Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.


Last update: August 2003